Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

365 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials.
Zhou JG, Huang L, Jin SH, Xu C, Frey B, Ma H, Gaipl US. Zhou JG, et al. ESMO Open. 2020 Feb;5(1):e000621. doi: 10.1136/esmoopen-2019-000621. ESMO Open. 2020. PMID: 32079622 Free PMC article.
Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
Schweizer C, Schubert P, Rutzner S, Eckstein M, Haderlein M, Lettmaier S, Semrau S, Gostian AO, Frey B, Gaipl US, Zhou JG, Fietkau R, Hecht M. Schweizer C, et al. Among authors: zhou jg. Eur J Cancer. 2020 Nov;140:55-62. doi: 10.1016/j.ejca.2020.09.001. Epub 2020 Oct 9. Eur J Cancer. 2020. PMID: 33045663 Clinical Trial.
Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.
Zhou JG, Donaubauer AJ, Frey B, Becker I, Rutzner S, Eckstein M, Sun R, Ma H, Schubert P, Schweizer C, Fietkau R, Deutsch E, Gaipl U, Hecht M. Zhou JG, et al. J Immunother Cancer. 2021 Feb;9(2):e001845. doi: 10.1136/jitc-2020-001845. J Immunother Cancer. 2021. PMID: 33593828 Free PMC article.
Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors.
Griewing LM, Schweizer C, Schubert P, Rutzner S, Eckstein M, Frey B, Haderlein M, Weissmann T, Semrau S, Gostian AO, Müller SK, Traxdorf M, Iro H, Zhou JG, Gaipl US, Fietkau R, Hecht M. Griewing LM, et al. Among authors: zhou jg. BMC Cancer. 2021 Mar 24;21(1):314. doi: 10.1186/s12885-021-08006-0. BMC Cancer. 2021. PMID: 33761922 Free PMC article.
Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer.
Semrau S, Gostian AO, Traxdorf M, Eckstein M, Rutzner S, von der Grün J, Illmer T, Hautmann M, Klautke G, Laban S, Brunner T, Tamaskovics B, Frey B, Zhou JG, Geppert CI, Hartmann A, Balermpas P, Budach W, Gaipl U, Iro H, Fietkau R, Hecht M. Semrau S, et al. Among authors: zhou jg. Cancers (Basel). 2021 Apr 19;13(8):1959. doi: 10.3390/cancers13081959. Cancers (Basel). 2021. PMID: 33921668 Free PMC article.
365 results